PGT-A – Kromos

PGT-A

Screening of embryos during IVF to improve the chances of successful implantation, pregnancy and childbirth.

Free shipping

Across Georgia

Control of biopsy

Lab partners go through a test biopsy

Independent interpretation

The final result is checked by three of our specialists

←

→

PGT-A (Preimplantation genetic testing for aneuploidy) is the screening of embryos in a cycle of assisted reproductive technology for the chromosomal abnormalities presence before transfer to the uterine cavity in order to increase the likelihood of successful pregnancy achieving.

PGT-A identifies:

Aneuploidy
Partial (segmental) aneuploidy
Mosaicism

Unbalanced translocations
Some types of polyploidy

A lot of factors influence the pregnancy development, but chromosomal abnormalities are the most common cause of a pregnancy loss.

40%–75%prevalence of chromosomal abnormalities identified during spontaneous abortion, according to world statistics

Indications for the study

Late reproductive age of a woman — 35 years and older
Recurrent pregnancy loss (history of 2 or more spontaneous abortions/miscarriages)
Recurrent implantation failure (3 failed embryotransfers in women under 35 and 2 in women 35 and older)

Severe spermatogenesis failure in men (oligoasthenozoospermia, oligozoospermia, azoospermia)
Balanced chromosomal rearrangements (Robertsonian translocations, certain reciprocal translocations and inversions, as well as other numerical and structural chromosomal abnormalities) .

An increased frequency of chromosomal abnormalities in embryos is assumed in all these groups.

Procedure of the study

At Kromos PGT-A is conducted using the NGS (Next Generation Sequencing) method, which allows to most accurately and quickly select embryos without chromosomal abnormalities for transfer to the uterine cavity.

The NGS method allows to analyze all the chromosomes of the embryo, as well as to identify mosaicism and unbalanced chromosomal rearrangements.

An IVF cycle can promote significantly risk reducing of failed implantation, pregnancy loss, and improve the chances of having a healthy baby using PGT-A.

Embryo cells growing

Biopsy of trophectoderm at the blastocyst stage

Cells are taken for analysis using a biopsy needle. Then the cells are sent to the laboratory for assay.

Whole genome amplification

Whole genome amplification (WGA) and library preparation for chip applying.

Ion Semiconductor Sequencing

Bioinformatics analysis

Result of the assay

Report generation based on the data obtained.

More than 2/3 of embryos contain chromosomal abnormalities (numerical or structural)

Later maternal age is accociated with significant increase of the percent of embryos with chromosomal pathology, and the likelihood of a successful IVF attempt without genetic testing is significantly reduced.

Such aneuploid embryos can be selected for transfer because they do not visually differ from embryos without chromosomal abnormalities.

On the 3—5th day of embryo development, trophectoderm cells are biopsied and PGT-A is conducted.

PGT-A makes it possible to identify and select an embryo without chromosomal abnormalities, that improves the chances of implantation and pregnancy.

According to statistics, pregnancy with the help of ART occurs in about 35% of all cases.

Quality control at each stage of the study:

Pre-analytical

Carrying out a test biopsy, monitoring compliance with the regime of transportation and storage.

Analytical

Minimization of errors due to a more convenient protocol for combining and cleaning libraries, automating sample preparation.

Post-analytical

Data analysis and independent interpretation by three specialists, minimization of subjective decisions through the neural network development and teaching.

PGT-A at Kromos

Technology

The NGS method makes it possible to analyze all the chromosomes of the embryo, as well as to identify mosaicism and unbalanced chromosomal rearrangements